Each WG member was assigned one or more scope elements and reviewed the existing relevant Toolkit measures and protocols, appropriate literature, and current clinical and research tools used for data collection to recommend measures and protocols to vet. Most of the WG review occurred during a 1-day in-person meeting; additional discussions were accomplished via teleconferences. All of this occurred over an 8-month time period in 2014-2015 and resulted in the WG achieving a consensus regarding 16 measures after identifying and vetting a total of 51 measures. The WG used the SC criteria (e.g., clearly defined, well-established, reproducible, low burden, used in a major study) for this selection and were mindful of the need to complement existing PhenX Toolkit content.
RESULTS
Sixteen new measures (see Table 1 ) were added to the PhenX Toolkit in April 2015 (see https://www.phenxtoolkit.org/index. php?pageLink=browse.measures&id=220000). Most measures (e.g., family history, growth charts, bone age, and body proportions) are broadly applicable to rare genetic conditions research. Measures were not identified and subsequently were not recommended for each organ system because standardized protocols are not available (e.g., skin conditions) or tools for those phenotypes were already covered by existing Toolkit measures (e.g., ocular). Ideally, PhenX measures include nonproprietary protocols, but two proprietary protocols-the Disability Index and the Scale of Developmental Domains of Early Childhood-were included in this domain because they were the most commonly used. Owing to the complexity of assessing rare genetic condition phenotypes, nine of these are considered high-burden measures (e.g., two require specialized training, two take more than 15 minutes to administer to an unaffected individual, and five require both training and more time). Details regarding the burden appear in the Requirements section for each protocol.
Guidelines from the Human Genome Variation Society (HGVS), which were used to properly name genetic variants, were added as Supplemental Information (SI) as an additional resource for researchers. Although highly relevant to rare genetic condition research, the guidelines were not a standardized protocol and did not meet the SC selection criteria for inclusion in the Toolkit.
To illustrate the content of the Toolkit, three of the raregenetic-condition measures are described below. 
Growth charts
Abnormal growth is a feature of many rare genetic conditions, including Turner syndrome, Marfan syndrome, Noonan syndrome, and various forms of skeletal dysplasia. Growth charts provide information regarding deviations from typical growth patterns. This information, along with other clinical and laboratory findings, can assist investigators with their research. The World Health Organization and the Centers for Disease Control and Prevention growth charts were selected for the Growth Charts measure because they are the most common standard methods used in clinical and research practice to record growth. 5, 6 Ataxia rating scale Ataxia is a symptom of several rare neurologic conditions, including ataxia telangiectasia and the various forms of spinocerebellar ataxia (SCA). Because disorders that affect the cerebellum cause most genetic forms of ataxia, ataxia rating scales are used to assess the severity of cerebellar ataxia. The Scale for the Assessment and Rating of Ataxia (SARA) was selected because it has good metric properties and interrater reliability and is easily administered. 7 The validation procedures for the SARA involved three large multicenter trials including patients with SCA and non-SCA ataxia as well as controls. The SARA has been shown to be a reliable and valid scale for measuring ataxia, with scores that correlate closely with other scales of ataxia as well as with activities of daily living.
DISCUSSION
Clinicians and researchers may wish to seriously consider incorporating PhenX measures into their own practice and research efforts because meta-analyses with the standardized measures could lead to genetic discoveries. Because the PhenX Toolkit resource facilitates cross-study analyses, the measures should be of particular interest to rare-condition researchers because of the limited sample size in each trial or study. In addition, these approaches may expand the existing understanding of some genetic conditions and lead to improved services and health for those with these conditions.
The rare-genetic-condition measures can be accessed by users with varying levels of experience with rare genetic conditions. For instance, protocols are applicable to study designs that include individuals who have already been diagnosed or are being evaluated, or both. As a result, they are beneficial to researchers who have experience with a specific rare condition, such as cystic fibrosis, as well as researchers who work with diseases for which a diagnosis is elusive.
Along with the research benefits to investigators of the raregenetic-condition measures, there are limitations. For instance, the WG could not identify standard low-burden measures for certain organ or sensory systems, such as gastrointestinal, ocular, and auditory systems. Another challenge was identifying a standard measure for newborn screening. Although each state conducts such screening, the conditions for which each state screens vary, as do their cutoffs for what constitutes disease. As The HGVS guidelines for sequence variant nomenclature are a comprehensive guide on how to describe (i.e., name) any identified variant by a standardized method. Mutalyzer is a free online tool that is primarily used to check that the sequence variant descriptions follow the HGVS nomenclature guidelines.
All the measures are available at the following website, under the measure of interest: https://www.phenxtoolkit.org/index.php?pageLink=browse.measures&id=220000. a result, there was no WG consensus on a measure for newborn screening so it was not included in the Toolkit. Similarly, no standard screening panel for rare metabolic genetic conditions was identified. Instead, health-care providers base their laboratory-test orders on an individual's clinical evaluation and family history. Therefore, the WG did not include a measure for a metabolic screening panel.
In addition to the measures in the Rare Genetics Conditions domain, other measures and resources in the Toolkit are relevant to research in both common and rare genetic conditions. A collection of measures for sickle cell disease research was added to the Toolkit in July 2015. In addition, the Genetic Alliance (http://www.geneticalliance.org) led a crowd-sourcing effort to annotate PhenX measures for specific genetic conditions. Researchers are encouraged to use this tool to annotate protocols for other rare genetic conditions. For example, the Exercise Capacity/Six-Minute Walk Test is used to measure the response to medical interventions in patients with moderate to severe heart or lung disease, and it is used as an outcome measure for people with Duchenne muscular dystrophy. 8 The annotation tool is available on the Resources tab of the PhenX Toolkit.
The Toolkit has several features that make it a user-friendly resource. Investigators can use the search function to find measures of interest and then add them to their personalized Toolkit to be downloaded as needed. In addition to the measures, data-collection worksheets and data dictionaries are available for each measure; these can be easily downloaded via the "My Toolkit" feature, which functions similarly to an online retailer's shopping cart. Investigators who become registered users of the PhenX Toolkit may save their work, share measures with colleagues, and receive updates about changes to the Toolkit. PhenX protocols are now available as "instrument zip" files on the Research Electronic Data Capture (REDCap) Shared Library website (https://redcap.vanderbilt.edu/consortium/library/search.php), making it easy for investigators to include PhenX measures in REDCap study designs.
CONCLUSION
Researchers of rare genetic conditions are encouraged to use the PhenX Toolkit when designing studies or adding measures to their research protocols. The use of standard measures facilitates cross-study analysis with limited sample sizes. The Toolkit gives investigators the capacity to expand original research and to look at common risk factors and overlapping phenotypes across rare genetic conditions and common and complex diseases.
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